Molbio Diagnostics IPO
Molbio Diagnostics IPO was a Mainboard book-built issue of ₹939.70 crore, comprising a Fresh Issue of ₹200 crore and an Offer for Sale of ₹739.70 crore. The price band was ₹768 to ₹807 per share, with a lot size of 18 shares. The IPO opened on August 10,
Molbio Diagnostics IPO Details
Molbio Diagnostics IPO bidding started on August 10, 2026 and ended on August 12, 2026. The allotment was finalized on August 13, 2026, refunds were initiated on August 14, and shares were credited to successful applicants' Demat accounts on August 14, 2026. The shares were listed on BSE and NSE on August 17, 2026.
Molbio Diagnostics IPO GMP
Molbio Diagnostics IPO GMP was reported at around ₹120 on the listing date. Against the final issue price of ₹807, this indicated an unofficial estimated price of around ₹927. The shares actually opened at ₹980 on both BSE and NSE, showing a listing gain of 21.44%. GMP is an unofficial grey-market indicator and does not guarantee the actual listing price.
Molbio Diagnostics IPO Timeline (Tentative)
Molbio Diagnostics IPO opened for subscription on August 10, 2026 and closed on August 12, 2026. The basis of allotment was finalized on August 13, refunds were initiated on August 14, and shares were credited to successful applicants' Demat accounts on August 14. The shares were listed on BSE and NSE on August 17, 2026.
| Event | Tentative Date |
|---|---|
| IPO Open Date | Mon, Aug 10, 2026 |
| IPO Close Date | Wed, Aug 12, 2026 |
| Basis of Allotment | Thu, Aug 13, 2026 |
| Initiation of Refunds | Fri, Aug 14, 2026 |
| Credit of Shares to Demat | Fri, Aug 14, 2026 |
| Listing Date | Mon, Aug 17, 2026 |
| IPO Opens | August 10, 2026 |
| IPO Closes | August 12, 2026 |
| Basis of Allotment | August 13, 2026 |
| Refund Initiation | August 14, 2026 |
| Credit of Shares to Demat | August 14, 2026 |
| Listing Date | August 17, 2026 |
Molbio Diagnostics IPO Lot Size
The Molbio Diagnostics IPO lot size was 18 shares. At the upper price band of ₹807 per share, one lot required a minimum investment of ₹14,526. Retail investors could apply for up to 13 lots, or 234 shares, amounting to ₹1,88,838.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 18 | 14,526 |
| Retail (Max) | 13 | 234 | 1,88,838 |
| S-HNI (Min) | 14 | 252 | 2,03,364 |
| S-HNI (Max) | 68 | 1,224 | 9,87,768 |
| B-HNI (Min) | 69 | 1,242 | 10,02,294 |
Molbio Diagnostics IPO Reservation
Molbio Diagnostics IPO offered 1,16,46,246 equity shares. The issue included 23,25,145 shares for QIBs, 17,43,860 shares for NIIs, 40,69,005 shares for retail investors and 20,519 shares reserved for eligible employees. Anchor investors were allotted 34,87,717 shares as part of the QIB portion.
Molbio Diagnostics IPO Subscription
Molbio Diagnostics IPO received 70.26x overall subscription by the close of bidding on August 12, 2026. The issue saw exceptionally strong demand from QIBs at 186.39x, while NIIs subscribed 49.80x, retail investors 12.96x and employees 13.28x.
| Category | Subscription (times) |
|---|---|
| QIB | 186.39x |
| NII | 49.80x |
| RII | 12.96x |
| Employee | 13.28x |
| Total | 70.26x |
About Molbio Diagnostics
Molbio Diagnostics Limited is a point-of-care diagnostics company focused on developing, manufacturing and commercialising rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed the Truenat platform, a portable, battery-operated real-time PCR-based molecular diagnostics system designed to bring molecular testing closer to patients, including in resource-limited and decentralised healthcare settings.
Through its Truenat platform and diagnostic assays, Molbio provides molecular testing solutions covering more than 30 diseases. The company's portfolio is supported by research and development capabilities through its wholly owned subsidiary Bigtec Labs. It has also expanded into adjacent healthcare areas through businesses and subsidiaries involved in digital pathology, radiology and breast health screening.
Molbio has a global presence and its products are used across multiple countries by government health programmes, hospitals, diagnostic laboratories and other healthcare institutions. The company has continued to invest in manufacturing capacity, research and development and product expansion, with its Truenat platform forming a key part of its molecular diagnostics business.
Strengths
- Molbio has a proprietary point-of-care molecular diagnostics platform with an established product portfolio.
- Its Truenat technology is designed for decentralised testing and has applications across a broad range of infectious diseases.
- The company also has established research and development capabilities through Bigtec Labs and a presence across international markets.
Risks to Consider
- The company operates in a highly regulated healthcare and diagnostics industry where product development, regulatory approvals and compliance are important to its growth.
- Delays in obtaining approvals for new products, unsuccessful research and development efforts, changes in healthcare policies and demand fluctuations can affect its business.
- The company also increased its borrowings substantially in FY2026, which is an important factor for investors to consider.
Molbio Diagnostics Financials (₹ Cr)
10. The application amount will be blocked in your bank account. If shares are allotted, the required amount will be debited; otherwise, the blocked amount will be released.
| Period | Revenue | PAT | Total Assets | Net Worth |
|---|---|---|---|---|
| FY2024 | ₹840.66 Cr | ₹83.54 Cr | ₹1,221.06 Cr | ₹807.94 Cr |
| FY2025 | ₹1,027.94 Cr | ₹138.58 Cr | ₹1,461.56 Cr | ₹952.95 Cr |
| FY2026 | ₹1,455.17 Cr | ₹164.14 Cr | ₹2,148.42 Cr | ₹1,144.68 Cr |
KPIs & Valuation
At the upper price band of ₹807, Molbio Diagnostics was valued at approximately 55.43x FY2026 earnings on a pre-issue basis and 56.67x on a post-issue basis. FY2026 pre-IPO EPS was ₹14.56, while the company reported RoNW of 14.55%, ROE of 15.59% and ROCE of 17.55%.
Objects of the Issue
The Molbio Diagnostics IPO comprised a Fresh Issue of ₹200 crore and an Offer for Sale of ₹739.70 crore. The company proposed to use the net proceeds from the Fresh Issue primarily for capital expenditure related to a research and development facility and Centre of Excellence, purchase of plant and machinery for its manufacturing units, and general corporate purposes. The Offer for Sale proceeds were received by the selling shareholders.
- The company proposed to utilise the IPO proceeds for funding capital expenditure towards setting up infrastructure for a research and development facility, Centre of Excellence and connected office space.
- The company also proposed to fund capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and the Visakhapatnam Unit.
- The remaining portion of the Fresh Issue proceeds was proposed to be used for general corporate purposes.
Promoters, Lead Managers & Registrar
Molbio Diagnostics Limited is promoted by Chandrasekhar Bhaskaran Nair, Exxora Trading LLP, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Sriram Natarajan. The Book Running Lead Managers were Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited. KFin Technologies Limited acted as the Registrar to the Issue.
Promoters
Lead Managers (BRLM)
Registrar
| Name | KFin Technologies Limited |
|---|---|
| Phone | +91 40 6716 2222 / 1800 309 4001 |
| molbio.ipo@kfintech.com | |
| Website | www.kfintech.com |
Molbio Diagnostics IPO Review
Molbio Diagnostics operates in the growing point-of-care molecular diagnostics segment and has built a differentiated business around its Truenat platform. Its combination of proprietary technology, diagnostic assays, research capabilities and international presence provides a base for further expansion in decentralised healthcare testing.
The company's financial performance improved substantially during the reported period. Total income increased from ₹840.66 crore in FY2024 to ₹1,027.94 crore in FY2025 and ₹1,455.17 crore in FY2026, while PAT increased from ₹83.54 crore to ₹138.58 crore and then ₹164.14 crore over the same period.
However, the IPO valuation was relatively high, with the issue priced at 55.43x pre-issue P/E and 56.67x post-issue P/E at the upper price band. Investors should therefore consider the company's growth prospects, regulatory environment, R&D requirements, borrowing levels and valuation before making an investment decision.
How to Apply
Molbio Diagnostics IPO applications could be made through ASBA or UPI. The minimum application was 1 lot of 18 shares, requiring ₹14,526 at the upper price band of ₹807.
1. Log in to your stockbroker app/website.
2. Go to the IPO section.
3. Select Molbio Diagnostics IPO.
4. Enter the number of lots you want to apply for.
5. Select the bid price. Retail investors can generally choose Cut-off when available.
6. Enter your valid UPI ID.
7. Submit the IPO application.
8. Open your UPI app when the mandate request arrives.
9. Approve the mandate using your UPI PIN.
10. The application amount will be blocked in your bank account. If shares are allotted, the required amount will be debited; otherwise, the blocked amount will be released.
Prospectus & Documents
Investors can refer to the company's DRHP, RHP and Prospectus for detailed information about the business, financial performance, risk factors, IPO structure and utilisation of the issue proceeds. Molbio Diagnostics maintains an official investor section containing its offer documents, including the Draft Red Herring Prospectus, Red Herring Prospectus and other investor documents.
Last updated Aug 26, 2026.